Category Archives: Evergreening

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

Source: Bloomberg Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.  The Initiative for Medicines, Access & Knowledge, a nonprofit focused on … Continue reading

Posted in Cancer, Evergreening, Hepatitis C, Patent, Uncategorized | Leave a comment

India grants Pfizer patent for pneumonia vaccine

Source: Live Mint India has granted Pfizer a patent for Prevnar 13 pneumonia vaccine, in spite of opposition from the heath group Médecins Sans Frontières (MSF) New Delhi: India has granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Indian patent for Pfizer’s pneumonia vaccine seen as a blow to aid group

Source: The HinduBusinessLine MUMBAI, AUGUST 22:   The grant of an Indian patent to Pfizer’s Prevenar13, a pneumococcal conjugate vaccine, has raised the hackles of pro-health group MSF who are worried that it will hamper access to the vaccine. “It’s unfair … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

MSF criticizes Swiss pharma aims at upcoming India-EFTA trade talks

Source: Pharma Letter On May 30, 2017 (tomorrow), trade talks will resume for the India-EFTA (European Free Trade Association) free trade agreement (FTA) in Liechtenstein, between India and the EFTA countries of Switzerland, Norway, Iceland and Liechtenstein. Through this deal, … Continue reading

Posted in EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment